• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巯基化合物对环磷酰胺(NSC - 26271)代谢物的失活作用。

Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

作者信息

Draeger J, Peter G, Hohorst H J

出版信息

Cancer Treat Rep. 1976 Apr;60(4):355-9.

PMID:1277211
Abstract

The reaction of 4-hydroxycyclophosphamide (4-hydroxy-CP) with sulfhydryl (SH) compounds was studied, and although the cytotoxic activity was lost a significant stabilization of the alkylating capacity was observed at the same time. We were able to show that the reaction of 4-hydroxy-CP with thiols lead to an equilibrium between the reaction product and the starting substrates. On the basis of this equilibrium the increased stabilization of the alkylating capacity of the 4-hydroxy-CP derivatives by raising the SH concentration can be explained. The different degrees of stabilization depending on the structure of the thiol results from different equilibria. the effect on the toxification reaction resulting from this equilibrium, in connection with the tautomeric equilibrium between 4-hydroxy-CP and aldophosphamide, is discussed.

摘要

研究了4-羟基环磷酰胺(4-hydroxy-CP)与巯基(SH)化合物的反应,虽然细胞毒性活性丧失,但同时观察到烷基化能力有显著的稳定作用。我们能够证明4-羟基-CP与硫醇的反应导致反应产物与起始底物之间达到平衡。基于这种平衡,可以解释通过提高SH浓度来增强4-羟基-CP衍生物烷基化能力的稳定性。取决于硫醇结构的不同程度的稳定性源于不同的平衡。讨论了这种平衡对毒化反应的影响,以及与4-羟基-CP和醛磷酰胺之间互变异构平衡的关系。

相似文献

1
Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.巯基化合物对环磷酰胺(NSC - 26271)代谢物的失活作用。
Cancer Treat Rep. 1976 Apr;60(4):355-9.
2
The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.环磷酰胺(NSC - 26271)的肿瘤生长抑制特异性问题:关于控制烷基化和细胞毒性活性反应的研究
Cancer Treat Rep. 1976 Apr;60(4):309-15.
3
Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.环磷酰胺(NSC-26271)相关的磷酰胺氮芥——最新进展与历史回顾
Cancer Treat Rep. 1976 Apr;60(4):337-46.
4
Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation.体内丙烯醛形成的研究:以3-羟基丙基巯基尿酸作为环磷酰胺(NSC-26271)活化指标的研究。
Cancer Treat Rep. 1976 Apr;60(4):327-35.
5
Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.4-氢过氧环磷酰胺(NSC-181815)的研究:一种简单的制备方法及其在合成新型“活性”含硫环磷酰胺(NSC-26271)衍生物中的应用。
Cancer Treat Rep. 1976 Apr;60(4):429-35.
6
Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Cancer Treat Rep. 1976 Apr;60(4):415-22.
7
Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.环磷酰胺(NSC - 26271)、环磷酰胺代谢物与普通氮芥化合物的体内外比较药理学研究。
Cancer Treat Rep. 1976 Apr;60(4):301-8.
8
Qualitative and quantitative investigations of cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and related compounds by field-desorption mass spectrometry.
Cancer Treat Rep. 1976 Apr;60(4):501-7.
9
Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.环磷酰胺(NSC - 26271)的选择性作用研究:组织可溶性酶对羟基化代谢物的失活作用
Cancer Treat Rep. 1976 Apr;60(4):321-6.
10
Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
Cancer Treat Rep. 1976 Apr;60(4):509-16.

引用本文的文献

1
Desferrioxamine protects against toxic damage to liver and kidney induced by cyclophosphamide.去铁胺可保护肝脏和肾脏免受环磷酰胺诱导的毒性损伤。
Int J Health Sci (Qassim). 2011 Jul;5(2 Suppl 1):15-7.
2
Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.α-干扰素与化疗药物的相互作用:对细胞毒性药物代谢及多药耐药性的影响
Med Oncol. 1995 Mar;12(1):9-14. doi: 10.1007/BF01571403.
3
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
4
Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.通过改良荧光测定法对活化异环磷酰胺和环磷酰胺人体药代动力学的比较研究。
J Cancer Res Clin Oncol. 1981;100(1):95-104. doi: 10.1007/BF00405906.
5
Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.活化环磷酰胺:一种基于酶机制的DNA聚合酶/3'-5'核酸外切酶自杀性灭活剂。
J Cancer Res Clin Oncol. 1984;107(3):195-8. doi: 10.1007/BF01032606.
6
Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.环磷酰胺、磷酰胺氮芥及某些活化恶唑磷对小鼠L1210白血病作用的观察
Invest New Drugs. 1984;2(2):149-54. doi: 10.1007/BF00232344.
7
Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.ASTA Z 7557(国际非专利药品名称:马磷酰胺,顺式-4-磺基乙硫基环磷酰胺)的化学特性,4-羟基环磷酰胺的一种稳定衍生物 。
Invest New Drugs. 1984;2(2):133-9. doi: 10.1007/BF00232342.
8
Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.3'-5'核酸外切酶对“活化”环磷酰胺的酶促毒化作用。
J Cancer Res Clin Oncol. 1983;105(1):27-9. doi: 10.1007/BF00391828.
9
Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.美司钠和半胱氨酸对活化环磷酰胺全身毒性及治疗效果的影响。
J Cancer Res Clin Oncol. 1987;113(2):160-5. doi: 10.1007/BF00391439.
10
Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.环磷酰胺和磷酰胺芥在大鼠体内的脑和血浆药代动力学及抗癌活性
Cancer Chemother Pharmacol. 1990;27(1):1-7. doi: 10.1007/BF00689268.